Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Depreciation & Amortization (CF) (2019 - 2023)

Alx Oncology Holdings' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $207000.0 for Q4 2023.

  • For Q4 2023, Depreciation & Amortization (CF) rose 97.14% year-over-year to $207000.0; the TTM value through Dec 2023 reached $836000.0, up 144.44%, while the annual FY2025 figure was $706000.0, 19.04% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2023 was $207000.0 at Alx Oncology Holdings, down from $209000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $213000.0 in Q1 2023 and bottomed at $5000.0 in Q3 2020.
  • The 5-year median for Depreciation & Amortization (CF) is $89500.0 (2022), against an average of $91888.9.
  • The largest annual shift saw Depreciation & Amortization (CF) crashed 95.58% in 2021 before it skyrocketed 1483.33% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $112000.0 in 2019, then plummeted by 95.54% to $5000.0 in 2020, then surged by 580.0% to $34000.0 in 2021, then skyrocketed by 208.82% to $105000.0 in 2022, then soared by 97.14% to $207000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Depreciation & Amortization (CF) are $207000.0 (Q4 2023), $209000.0 (Q3 2023), and $207000.0 (Q2 2023).